Paul McGarry
About Paul McGarry
Paul McGarry, 58, is Interim Chief Financial Officer (principal financial and accounting officer) of HF Foods Group Inc., effective October 15, 2025, after serving as Vice President, Corporate Controller since February 2025; he holds a B.S. in Accounting from The Pennsylvania State University and is a Certified Public Accountant . His initial employment as Corporate Controller commenced on February 25, 2025, under an at‑will arrangement with bi‑weekly payroll, reporting initially to then‑CFO Cindy Yao; during the interim CFO period he reports directly to CEO Felix Lin . Prior experience spans public‑company governance, enterprise finance and operational transformation across American Battery Technology Company, Alimera Sciences, Rockwell Medical, Alyvant, Champions Oncology, and Deloitte .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| American Battery Technology Company | Corporate Financial Controller | Jul 2024–Feb 2025 | Oversaw financial operations and strengthened internal-control environment |
| Alimera Sciences, Inc. | Financial executive consultant | 2023–2024 | Provided forecasting, financial reporting, and internal-control advisory services |
| Rockwell Medical, Inc. | SVP Finance & Chief Accounting Officer | 2019–2023 | Senior finance leadership and accounting oversight |
| Alyvant, Inc. | Corporate Financial Controller | 2018–2019 | Corporate finance and controls |
| Champions Oncology, Inc. | Corporate Financial Controller | 2011–2018 | Corporate finance, reporting, controls |
| Deloitte & Touche LLP | Audit Manager (Assurance & Advisory) | Early career (years not specified) | Audit and advisory services |
Fixed Compensation
| Component | Terms | Effective Date |
|---|---|---|
| Base Salary | $240,000 annual salary, paid bi‑weekly | 02/25/2025 |
| Interim Monthly Stipend | $10,000 per month during interim CFO period; pro‑rated for partial months | 10/15/2025 |
| One‑Time 10‑K Filing Bonus | $50,000 lump sum if FY2025 Form 10‑K is filed on or before the deadline; paid within 21 business days of timely filing | During interim CFO period |
Performance Compensation
| Incentive Type | Metric/Structure | Target/Weighting | Actual/Payout | Vesting |
|---|---|---|---|---|
| Annual Bonus | Discretionary annual bonus opportunity | 30% of base salary | Not disclosed in Offer Letter/8‑K | Not disclosed |
| Equity Grant Eligibility | Annual long‑term equity grant, subject to Compensation Committee approval under 2018 Omnibus Plan | Target grant equal to 30% of base salary | Not disclosed | Not disclosed |
Note: The Offer Letter and amendment do not specify performance metrics (e.g., revenue, EBITDA, TSR) or vesting schedules for bonus/equity; the annual bonus is explicitly discretionary .
Employment Terms
| Term | Details |
|---|---|
| Employment Start (Controller) | February 25, 2025 |
| Interim CFO Appointment | Effective October 15, 2025 |
| Reporting Relationship | Initially reported to CFO Cindy Yao; during interim period reports to CEO Felix Lin |
| Employment Relationship | At‑will; terminable by either party at any time |
| Work Location | Company offices at 6325 South Rainbow Blvd Suite 420, Las Vegas, NV 89118 |
| Paid Time Off | Unlimited vacation plan; sick time per applicable laws; paid holidays observed |
Compensation Structure Analysis
- Increased fixed pay during interim tenure via $10,000 monthly stipend and a contingent $50,000 filing bonus shifts mix toward cash and near‑term incentives, reducing equity‑linked at‑risk pay in the interim period .
- Annual bonus is discretionary (not metric‑tied) and equity is committee‑approved, indicating limited formal pay‑for‑performance linkages disclosed in current agreements; performance metrics and vesting details are not specified in the Offer Letter/amendment .
Risk Indicators & Governance Notes
- CFO transition: McGarry’s appointment as Interim CFO following Cindy Yao’s separation (without cause per her offer letter) signals leadership change; the company disclosed no disagreements on financial disclosures or accounting matters tied to her departure .
- Related party and family relationships: None requiring disclosure; no arrangements or understandings led to McGarry’s appointment .
- Filings execution: McGarry is signatory for recent 8‑Ks, including exhibits and press releases, reinforcing accountability for timely reporting .
Investment Implications
- Alignment: Compensation currently emphasizes fixed cash and a process‑contingent cash bonus (timely 10‑K filing), with discretionary annual bonus and committee‑approved equity; lack of disclosed performance metrics/vesting reduces transparency of pay‑for‑performance alignment .
- Retention/Execution: Interim status and direct reporting to the CEO suggest near‑term execution urgency on financial controls and reporting; stipend/bonus encourage stability through FY2025 reporting .
- Trading Signals: Leadership transition may elevate near‑term reporting/compliance focus; absence of disclosed ownership, pledging, or insider sale data in available filings limits read‑through on potential selling pressure. Continuous monitoring for Form 4s and the FY2025 proxy will be critical to assess equity alignment and potential overhangs.